Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus
Open Access
- 12 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 810-821
- https://doi.org/10.1016/j.omtm.2020.04.009
Abstract
No abstract availableFunding Information
- Defense Threat Reduction Agency
This publication has 50 references indexed in Scilit:
- Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent VaccinePLoS Pathogens, 2013
- Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic FeverPLOS ONE, 2012
- Postexposure antibody prophylaxis protects nonhuman primates from filovirus diseaseProceedings of the National Academy of Sciences of the United States of America, 2012
- A DNA Vaccine for Venezuelan Equine Encephalitis Virus Delivered by Intramuscular Electroporation Elicits High Levels of Neutralizing Antibodies in Multiple Animal Models and Provides Protective Immunity to Mice and Nonhuman PrimatesClinical and Vaccine Immunology, 2011
- Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA VaccineJournal of Virology, 2011
- Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancersGene Therapy, 2010
- Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection systemVaccine, 2009
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccinesNature, 2008
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004